218 related articles for article (PubMed ID: 29378174)
1. Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.
Zhang S; Wang J; Wang H; Fan L; Fan B; Zeng B; Tao J; Li X; Che L; Cigliano A; Ribback S; Dombrowski F; Chen B; Cong W; Wei L; Calvisi DF; Chen X
Am J Pathol; 2018 Apr; 188(4):995-1006. PubMed ID: 29378174
[TBL] [Abstract][Full Text] [Related]
2. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
[TBL] [Abstract][Full Text] [Related]
3. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
[TBL] [Abstract][Full Text] [Related]
5. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
Liang B; Wang H; Qiao Y; Wang X; Qian M; Song X; Zhou Y; Zhang Y; Shang R; Che L; Chen Y; Huang Z; Wu H; Monga SP; Zeng Y; Calvisi DF; Chen X; Chen X
Hepatology; 2023 Jun; 77(6):1929-1942. PubMed ID: 35921500
[TBL] [Abstract][Full Text] [Related]
6. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
[TBL] [Abstract][Full Text] [Related]
7. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.
Jeong SH; Kim HB; Kim MC; Lee JM; Lee JH; Kim JH; Kim JW; Park WY; Kim SY; Kim JB; Kim H; Kim JM; Choi HS; Lim DS
J Clin Invest; 2018 Mar; 128(3):1010-1025. PubMed ID: 29400692
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of Hippo kinase signalling in human hepatic malignancies.
Li H; Wolfe A; Septer S; Edwards G; Zhong X; Abdulkarim AB; Ranganathan S; Apte U
Liver Int; 2012 Jan; 32(1):38-47. PubMed ID: 22098159
[TBL] [Abstract][Full Text] [Related]
9. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
[TBL] [Abstract][Full Text] [Related]
10. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
[TBL] [Abstract][Full Text] [Related]
11. Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma.
Sugimachi K; Nishio M; Aishima S; Kuroda Y; Iguchi T; Komatsu H; Hirata H; Sakimura S; Eguchi H; Bekki Y; Takenaka K; Maehara Y; Suzuki A; Mimori K
Oncology; 2017; 93(1):67-74. PubMed ID: 28448997
[TBL] [Abstract][Full Text] [Related]
12. Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis.
Kim W; Khan SK; Gvozdenovic-Jeremic J; Kim Y; Dahlman J; Kim H; Park O; Ishitani T; Jho EH; Gao B; Yang Y
J Clin Invest; 2017 Jan; 127(1):137-152. PubMed ID: 27869648
[TBL] [Abstract][Full Text] [Related]
13. Interacting network of Hippo, Wnt/β-catenin and Notch signaling represses liver tumor formation.
Kim W; Khan SK; Yang Y
BMB Rep; 2017 Jan; 50(1):1-2. PubMed ID: 27881216
[TBL] [Abstract][Full Text] [Related]
14. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.
Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW
BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973
[TBL] [Abstract][Full Text] [Related]
15. JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.
Ye J; Li TS; Xu G; Zhao YM; Zhang NP; Fan J; Wu J
Cancer Res; 2017 Oct; 77(19):5287-5300. PubMed ID: 28775168
[TBL] [Abstract][Full Text] [Related]
16. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
17. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
18. Insulin receptor substrate 2: a bridge between Hippo and AKT pathways.
Jeong SH; Lim DS
BMB Rep; 2018 May; 51(5):209-210. PubMed ID: 29699606
[TBL] [Abstract][Full Text] [Related]
19. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.
Ho C; Wang C; Mattu S; Destefanis G; Ladu S; Delogu S; Armbruster J; Fan L; Lee SA; Jiang L; Dombrowski F; Evert M; Chen X; Calvisi DF
Hepatology; 2012 Mar; 55(3):833-45. PubMed ID: 21993994
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
Liu Y; Wang X; Yang Y
Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
